Factors associated with reported pain on injection and reactogenicity to an OMV meningococcal B vaccine in children and adolescents
Open Access
- 23 April 2015
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 11 (7) , 1872-1877
Abstract
Pain on vaccine injection and subsequent site reactions of pain and swelling may influence confidence in vaccines and their uptake. This study aimed to identify factors associated with reported pain on injection and reactogenicity following administration of a strain specific meningococcal B outer membrane vesicle vaccine. A retrospective analysis of data was conducted from a phase II single center randomized observer-blind study that evaluated the safety, reactogenicity and immunogenicity of this vaccine in 2 cohorts of healthy 8 to 12 y old children. Vaccine administration technique was observed by an unblinded team member and the vaccine administrator instructed on standardized administration. Participants kept a daily diary to record local reactions (erythema, induration and swelling) and pain for 7 d following receipt of the vaccine. Explanatory variables were cohort, vaccine, age, gender, ethnicity, body mass index, atopic history, history of frequent infections, history of drug reactions, pain on injection, vaccinator, school population socioeconomic status, serum bactericidal antibody titer against the vaccine strain NZ98/254, and total IgG. Univariate and multivariable analyses were conducted using ordinal logistic regression for factors relating to pain on injection and reactogenicity. Perceived pain on injection was related to vaccine formulation, vaccine administrator and ethnicity. Reactogenicity outcomes varied with ethnicity and vaccine administrator. Maintaining community and parental confidence in vaccine safety without drawing attention to differences between individuals and groups is likely to become increasingly difficult. Vaccine administration technique alone has the potential to significantly reduce pain experienced on injection and local vaccine reactions.Keywords
This publication has 17 references indexed in Scilit:
- A Quantitative Review of Ethnic Group Differences in Experimental Pain Response: Do Biology, Psychology, and Culture Matter?Pain Medicine, 2012
- Multicenter, Open‐Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in InfancyClinical Infectious Diseases, 2010
- Epidemiology of Pertussis and Haemophilus influenzae type b Disease in Canada With Exclusive Use of a Diphtheria-Tetanus-Acellular Pertussis-Inactivated Poliovirus-Haemophilus influenzae type b Pediatric Combination Vaccine and an Adolescent-Adult Tetanus-Diphtheria-Acellular Pertussis VaccineThe Pediatric Infectious Disease Journal, 2009
- Phase II meningococcal B vesicle vaccine trial in New Zealand infantsArchives of Disease in Childhood, 2008
- Barriers and facilitators to human papillomavirus vaccination among Chinese adolescent girls in Hong Kong: a qualitative-quantitative studySexually Transmitted Infections, 2008
- Immunogenicity, Reactogenicity, and Safety of a P1.7b,4 Strain-Specific Serogroup B Meningococcal Vaccine Given to PreteensClinical and Vaccine Immunology, 2007
- New Zealand Epidemic Strain Meningococcal B Outer Membrane Vesicle Vaccine in Children Aged 16–24 MonthsThe Pediatric Infectious Disease Journal, 2007
- Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: Beginning of epidemic controlVaccine, 2006
- Vaccine Safety Controversies and the Future of Vaccination ProgramsThe Pediatric Infectious Disease Journal, 2005
- MeNZB?: a safe and highly immunogenic tailor-made vaccine against the New Zealand serogroup B disease epidemic strainVaccine, 2005